We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04901325
Recruitment Status : Recruiting
First Posted : May 25, 2021
Last Update Posted : September 2, 2022
Information provided by (Responsible Party):
Alex Ortega Loayza, Oregon Health and Science University

Brief Summary:
An Open-Label, Proof-Of-Concept, Study of Baricitinib for the Treatment of Pyoderma Gangrenosum

Condition or disease Intervention/treatment Phase
Pyoderma Gangrenosum Skin Diseases Wound Heal Pyoderma Skin Ulcer Drug: Baricitinib Phase 2

Detailed Description:
This is a Phase II study that will be open label and include a total of 20 patients who will receive the investigational product. PG will be defined by the investigator and a second reviewer on the basis of results from clinical, histological and laboratory assessments. These patients will undergo 24 weeks of baricitinib dosed daily and stable dose of prednisone dosed daily with follow-up until week 36.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)
Actual Study Start Date : September 29, 2021
Estimated Primary Completion Date : July 5, 2023
Estimated Study Completion Date : December 31, 2023

Resource links provided by the National Library of Medicine

Drug Information available for: Baricitinib

Arm Intervention/treatment
Experimental: Baricitinib for PG
Subjects with PG will be treated with 4 mg once daily of baricitinib for 24 weeks in addition to starting stable dose (at least 2 weeks) of prednisone at 30 mg daily. Prednisone will be tapered based on a pre-established algorithm assessed by investigator.
Drug: Baricitinib
Subjects with PG will be treated with 4 mg once daily of baricitinib for 24 weeks.
Other Name: Olumiant

Primary Outcome Measures :
  1. Healing [ Time Frame: Week 24 ]
    defined as the proportion of patients with complete re-epithelization of the target ulcer at week 24.

Secondary Outcome Measures :
  1. Physician Global Assessment (PGA) [ Time Frame: Week 36 ]

    Assessing the proportion of patients that show target ulcer healing in response to study treatment as measured by achieving PGA between 0 and 1 after treatment with baricitinib at week-36 52. This scale has been used in previous trials:

    1. 0 = total resolution of target ulcer with no signs of active PG
    2. 1= almost completely healed target ulcer with only minimal signs of active PG
    3. 2 = evidence of target ulcer healing which involves at least 50% of ulcer/ulcer margin
    4. 3 = evidence of target ulcer healing which involves less than 50% of ulcer/margin
    5. 4 = no evidence of target healing ulcer

  2. Percent change in lesion surface area [ Time Frame: Week 0 and 24 ]
    The percent change in surface area of target lesion of PG (two-dimensional surface in cm²) using digital photography and acetate tracing at Week 0 and Week 24

  3. Mean change in lesion surface area [ Time Frame: Week 0 and 24 ]
    The mean change in surface area of target lesion of PG (two-dimensional surface in cm²) using digital photography and acetate tracing

  4. Mean change in Physician Global Assessment (PGA) [ Time Frame: Week 0 and 24 ]
    The mean change in Physician global assessment (PGA) 5-point scale at week 0 to week 24

  5. Participants receiving ≤8mg prednisone per day [ Time Frame: Over 24-week period of study. ]
    The proportion of participants who receive prednisone at a dose of 8 mg or less per day (physiological dose) over the 24-week period.

  6. Sustained healing [ Time Frame: Week 36 ]
    The proportion of patients with target ulcer that remains healed by week 36

  7. Decrease in ulcer area size [ Time Frame: Week 24 ]
    The proportion of patients with decrease in ulcer area size of at least 50% after treatment at week 24

  8. Time to healing [ Time Frame: Over 36-week period of study. ]
    Time to which sterile dressings are not required.

  9. Time to recurrence (weeks) [ Time Frame: 36 weeks ]
    Interval between target lesion healing and further episodes of PG at any site through the study.

  10. Number of treatment failures [ Time Frame: By week 24 ]
    Treatment intolerance, number of patients switching into standard of care or target lesion unhealed.

  11. Adverse reactions to medications [ Time Frame: Over 24-week period of study. ]
    Possibly-, probably- or related throughout the study.

  12. Quality of life change (as measured by the Dermatology Life Quality Index) [ Time Frame: Week 24 ]
    Proportion of subjects achieving a 4-point change in quality of life measured by the Dermatology Life Quality Index (DLQI) at week 24, and mean change in DLQI score at week 24. The DLQI is a validated tool for inflammatory skin conditions. It is a 10-question survey, scored 0 - 30 points. For inflammatory skin conditions, a 4-point change in DLQI score is considered clinically important.

  13. Mean change in quality of life (measured by Dermatology Life Quality Index) [ Time Frame: Week 0 and 24 ]
    Mean change in DLQI score from week 0 to week-24.

  14. Skin pain scale [ Time Frame: Week 0 to 24 ]
    Mean percentage in improvement in pain related to PG target ulcer measured by 0 - 10-point numeric pain rating scale (NRS) at week 0 and week-24. The pain NRS is a subject-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no pain" and 10 representing "worst pain imaginable."

Other Outcome Measures:
  1. Evaluation of cytokine gene expression [ Time Frame: Week 0 and week 24 ]
    15. Evaluation of cytokine gene expression before and after treatment in skin and blood samples

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Willingness to comply with study procedures/requirements
  • Capable of giving informed consent
  • Diagnosis of at least one PG ulcer by clinical, histological and laboratory assessments with a minimum wound size of 4 cm2.
  • Male age 18-99 who agree to not father a child or donate sperm while on study and at least 1 week following last dose of the study drug. If subject is a sexually active male and could cause a pregnancy, subject must be sure that female partner(s) are using birth control that works well or not have sex.
  • Female age 18-99; either of non-childbearing potential or of childbearing potential who test negative for pregnancy and agree to use at least two reliable methods of birth control or remain abstinent during the study and for at least 1 week following the last dose of baricitinib.
  • Classic PG defined as deep ulceration with undermining violaceous borders.
  • Are candidate for systemic therapy. All participants will be taking and clinically stable 30 mg (same ulcer size) of prednisone fort least two weeks at the start of the study. Patients must have discontinued immunosuppressive therapies (cyclosporine, azathioprine, mycophenolate mofetil, methotrexate, apremilast, dapsone) due to inadequate response or intolerance for at least 4 weeks prior to beginning the study drug.
  • Undergoing at least once a week standard of care wound care at home or wound care facility.
  • Willingness to travel to Oregon Health and Science University (OHSU) for all study visits, or living >30 miles from OHSU and willing/able to participate in remote videoconferencing visits with access to a computer with internet and webcam capabilities.

Exclusion Criteria:

  • Have history of malignancy or lymphoproliferative disease; or have signs or symptoms suggestive of possible lymphoproliferative disease, including lymphadenopathy or splenomegaly; or have active primary or recurrent malignant disease; or have been in remission from clinically significant malignancy for < 5years.
  • Patients with cervical carcinoma in situ, basal cell carcinoma or squamous cell carcinomas who have had active disease within 3 years of screening for this study. Active, untreated, acute or chronic infection (such as untreated tuberculosis), or immunocompromised to an extent that such that participation in the study would pose an unacceptable risk to the subject. (Treated infections such as latent tuberculosis after completion of the appropriate therapy are not excluded.)
  • Clinically serious infection or received intravenous antibiotics for an infection, within 4 weeks of randomization.
  • Active viral infection that, based on the investigator's clinical assessment, makes the subject and unsuitable candidate for the study.
  • Positive for human immunodeficiency virus, hepatitis B virus, or hepatitis C virus.
  • Symptomatic herpes zoster infection within 12 weeks of screening or recurrent or disseminated (even a single episode) herpes zoster.
  • Symptomatic herpes simplex at the time of randomization or disseminated (even a single episode) herpes simplex
  • History of disseminated opportunistic infections (e.g., listeriosis and histoplasmosis).
  • Have a history of venous thromboembolism (VTE), or are considered at high risk for VTE as deemed by the investigator, or have 2 or more of the following risk factors for VTE:

    1. Aged >65 years.
    2. Body mass index (BMI) >35 kg/m2.
    3. Oral contraceptive use and current smoker.
  • Creatinine Clearance <30 mL/min
  • Wound care debridement of any PG ulcer within 2 weeks.
  • Intralesional corticosteroids within 4 weeks of screening.
  • Previous exposure to a Janus kinase (JAK) inhibitor (ruxolitinib, tofacitinib, upadacitinib, filgotinib). For biologic therapies, the specific washout periods used will at least 4 weeks for anakinra, etanercept, infliximab, adalimumab, alefacept, golimumab, secukinumab, ixekizumab, risankizumab, guselkumab, tildrakizumab, canakinumab, ustekinumab and at least 24 weeks for rituximab or efalizumab.
  • Patients who are currently on immunosuppressive therapies or have not discontinued them for at least 4 weeks.
  • Clinically significant (per investigator's judgement) drug or alcohol abuse within the last 6 months preceding the Baseline Visit.
  • Have a live vaccine within 12 weeks prior to baseline or intend to have a live vaccine during the course of study.
  • Had any major surgery within 8 weeks prior to baseline or will require major surgery during the study, which in the opinion of the investigator would pose an unacceptable risk to the subject.
  • Recent (within past 6 months) cerebrovascular accident, myocardial infarction, coronary stenting. Uncontrolled hypertension - confirmed systolic blood pressure >160 mmHg or diastolic blood pressure >100 mm Hg.
  • Gastrointestinal (GI) perforation (other than appendicitis or penetrating injury), diverticulitis or significantly increased for GI perforation (within past 6 months) per investigator judgement; any condition could interfere with drug absorption including but not limited to short bowel syndrome.
  • Presence of significant uncontrolled respiratory, hepatic, renal, endocrine, hematologic, neurologic, or neuropsychiatric disorders, or abnormal laboratory screening values that, in the opinion of the investigator, pose an unacceptable risk to the subject if participating in the study or of interfering with the interpretation of the data.
  • Have clinical laboratory test results at screening that are outside the normal reference range of the population and are considered clinically significant, or have any of the following specific abnormalities: Neutrophil count <1500 cells/µL, lymphocyte count <500 cells/µL, platelet count <100,000 cells/µL, aspartate transaminase (AST) or alanine aminotransferase (ALT) > 2 times the upper limit of normal, hemoglobin <10 g/dL for male and female subjects, eGFR>60.
  • Women who are lactating or breastfeeding.
  • Have any other condition that precludes the subject from following and completing the protocol, in the opinion of the investigator.
  • Are investigator site personnel directly affiliated with this study and/or their immediate families (spouse, parent, child, or sibling).
  • Are currently enrolled in, or discontinued from a clinical trial involving an investigational product or non-approved use of a drug or device within the last 4 weeks or a period of at least 5 half-lives of the last administration of the drug, whichever is longer, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04901325

Layout table for location contacts
Contact: Alex G Ortega- Loayza, MD, MCR 503-418-3376 ortegalo@ohsu.edu
Contact: Morgan Vague, BA 713-628-4926 vague@ohsu.edu

Layout table for location information
United States, Oregon
Oregon Health and Science University Recruiting
Portland, Oregon, United States, 97239
Contact: Alex Ortega, MD, MCR    503-418-3376    ortegalo@ohsu.edu   
Contact: Morgan Vague, BA    7136284926    vague@ohsu.edu   
Sponsors and Collaborators
Oregon Health and Science University
Layout table for investigator information
Principal Investigator: Alex G Ortega-Loayza, MD, MCR Oregon Health & Science University, Department of Dermatology

Layout table for additonal information
Responsible Party: Alex Ortega Loayza, Associate Professor of Dermatology, School of Medicine, Oregon Health and Science University
ClinicalTrials.gov Identifier: NCT04901325    
Other Study ID Numbers: Baricitinib for PG Treatment
First Posted: May 25, 2021    Key Record Dates
Last Update Posted: September 2, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Alex Ortega Loayza, Oregon Health and Science University:
JAK Kinase Inhibitors
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases
Pyoderma Gangrenosum
Skin Ulcer
Skin Diseases, Vascular